You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
睿智醫藥(300149.SZ):量子醫療擬出資出資1.63億元與上海科岑、迪一優品共設合資公司 持股佔比51%
格隆匯 11-12 18:07

格隆匯 11 月 12日丨睿智醫藥(300149.SZ)公佈,2020年11月12日,公司第四屆董事會第二十七次會議審議通過了《關於控股子公司投資設立子公司暨提供履約擔保的議案》,董事會同意控股子公司量子醫療與上海科岑生物科技有限公司(以下簡稱“上海科岑”或“乙方”)、迪一優品(廣州)生物科技有限公司(以下簡稱“迪一優品”或“丙方”)共同出資3.2億元人民幣投資設立廣東開新睿智生物醫藥有限公司(以下簡稱“開新睿智”或“項目公司”,暫定名,以市場監督管理局核准為準),其中,量子醫療認繳出資1.6320億元,佔註冊資本的51%,上海科岑認繳出資10,880萬元,佔註冊資本的34%,迪一優品認繳出資4800萬元,佔註冊資本的15%。項目公司成立後,將為“創新生物藥一站式研發生產服務平台項目”建設與運營的法律主體。

同時,根據量子醫療與中新廣州知識城開發建設辦公室簽署的《研發生產服務平台投資合作協議》,量子醫療需對項目公司就項目建設、項目運營等義務向中新廣州知識城開發建設辦公室提供連帶保證責任,即項目公司違約且無法承擔對中新廣州知識城開發建設辦公室的違約責任時,量子醫療須根據中新廣州知識城開發建設辦公室要求先行賠付,預計賠付的責任上限不超過5000萬元。即使項目公司引入投資者,量子醫療仍須承擔連帶保證責任。為此,其他出資方就量子醫療提供的擔保將提供充足的保障措施,在擬簽署的《投資合作協議》中已詳細約定對量子醫療提供連帶擔保的保障條款,具體詳見本公告“四、投資合作協議的主要內容”。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account